跳至主要内容
临床试验/EUCTR2011-003317-41-DE
EUCTR2011-003317-41-DE进行中(未招募)不适用

Double-blind, randomized, clinical trial to compare the efficacy and safety of diclofenc 3% gel vs. Solaraze 3% gel vs. vehicle for the treatment of patients with actinic keratosis.

Dermapharm AG0 个研究点开始时间: 2011年9月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Dermapharm AG

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) immunocompetent men or women, 18 years or older
  • 2) written consent form
  • 3) diagnosis: actinic keratosis
  • 4) at least five (5) and no more than ten (10) clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions, each at least 4 mm in diameter, contained within a 25-cm² treatment area located on the face or bald scalp
  • 5) women of child bearing potential: use of a highly effective method of contraception during the whole course of the study
  • 6) women: negative pregnancy test prior to study start
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 330
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) presence of atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, sunburn or other possible confounding skin conditions in or near the treatment area
  • 2) use within six months prior to randomization of oral retinoids
  • 3) use within one month prior to randomization of immunomodulators or immunosuppressive therapies, interferon, oral corticosteroids or cytotoxic drugs
  • 4) use within six months prior to randomization on the face or bald scalp of chemical peel, dermabrasion, laser abrasion, PUVA therapy, or UVB therapy
  • 5) use within one month prior to randomization on the face or bald scalp of cryodestruction or chemodestruction, curettage, photodynamic therapy, surgical excision, topical 5-fluorouracil, topical corticosteroids, topical diclofenac, topical imiquimod, topical retinoids, or other treatment for actinic keratosis
  • 6) known allergy or hypersensitivity to diclofenac or other excipients in one of the test products
  • 7) known hypersensitivity reactions like asthma, rhinitis or urticaria to acetyl salicylic acid or other NSAIDs in the past
  • 8) active gastrointestinal ulceration or bleeding
  • 9) severe renal or hepatic impairment

研究者

发起方
Dermapharm AG

相似试验